PHILADELPHIA, Feb. 15, 2022 (GLOBE NEWSWIRE) — Scout Bio, a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions, today announced that it will present at two conferences in February 2022. They include:
- Animal Health, Nutrition and Technology Innovation Europe (In-person). Scout Bio is a sponsor of the event, and management will host a technical insights session reviewing the company’s platform and pipeline on February 22 at 3:15 p.m. GMT.
- Bank of America Securities Animal Health Summit (Virtual). Scout Bio Chief Executive Officer Mark Heffernan, Ph.D., will provide a corporate overview on Thursday, February 25, 2022 at 10:50-11:30 a.m. EST.
About Scout Bio
Scout Bio is a biotechnology company revolutionizing pet medicine by delivering a pipeline of biological proteins and one-time gene therapies for major chronic pet health conditions. Scout Bio’s AAV gene therapies are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Scout Bio has a research and development collaboration with the University of Pennsylvania’s Gene Therapy Program, a leader in the field of genetic medicine research. Scout Bio is a private company headquartered in Philadelphia, Pennsylvania. For more information, see www.scoutbio.co.
For further information, please contact:
Fran Gaconnier
Scout Bio
214.417.4142
[email protected]
Powered by WPeMatico
